WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annual Canaccord Genuity Growth Conference on August 12, 2015 at 3:30 pm EDT at the Intercontinental Hotel in Boston, MA.
The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay of the presentation will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation.
About Radius Health
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, which is completing Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 email@example.comSource:Radius Health